Ajaykumar D. Rao, MD, MMSc, FACP, Chief of the Section of Endocrinology, Diabetes and Metabolism and Associate Professor of Medicine at the Lewis Katz School of Medicine at Temple University and Associate Professor in the Center for Metabolic Disease Research at Temple University Hospital, provided perspective to Healthline on new research that found semaglutide (also known as Wegovy or Ozempic) may help lower the risk of developing cardiovascular disease. The research, presented at the European Congress on Obesity, found that multiple cardiovascular risk factors, including blood pressure, total cholesterol and triglycerides, decreased after a year of taking semaglutide. Dr. Rao was not involved in the study.
Weather Alert: A major winter storm is likely to impact the Philadelphia region this weekend into Monday. Temple Health remains open, though some appointments or services may be adjusted. Patients will be contacted directly if their visit is affected. Please check TempleHealth.org for updates and monitor myTempleHealth for changes to scheduled appointments.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH